



Acella Pharmaceuticals – Recall of NP Thyroid® (thyroid tablets)

- On May 22, 2020, [Acella Pharmaceuticals announced](#) a consumer-level recall of thirteen lots of [NP Thyroid \(thyroid tablets\)](#) because testing has found the recalled lots to be superpotent. The product may have up to 115.0% of the labeled amount of liothyronine (T3).
- The recalled lots were distributed nationwide in the U.S.

Product Description	NDC#	Lot# (Expiration Date)
NP Thyroid 30 mg tablets	42192-329-01	M329A19-1 (12/2020); M329H18-1 (07/2020); M329J18-1 (08/2020); M329J18-2 (08/2020); M329J18-3 (08/2020); M329M18-2 (11/2020)
NP Thyroid 60 mg tablets	42192-330-01	M330J18-2A (08/2020); M330J18-3 (08/2020)
NP Thyroid 90 mg tablets	42192-331-01	M331G18-1 (06/2020); M331J18-1 (08/2020); M331J18-2 (08/2020); M331M18-1 (11/2020); M331M18-2 (11/2020)

- NP Thyroid is composed of levothyroxine and liothyronine, and used to treat hypothyroidism.
- Patients being treated for hypothyroidism, who receive superpotent NP Thyroid, may experience signs and symptoms of hyperthyroidism which include, but are not limited to, weight loss, heat intolerance, fatigue, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances.
- Pregnant women who take superpotent NP Thyroid may also experience negative maternal and fetal outcomes including miscarriage and/or impairment to fetal development. Patients should talk to their healthcare professional before they stop taking their NP Thyroid medicine.
- To date, Acella has received two reports of adverse events known to be related to this recall.
- Patients who are currently taking NP Thyroid from the lots being recalled should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.
- Anyone with an existing inventory of the recalled product should stop use and distribution and quarantine the product immediately.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

- Contact Acella Pharmaceuticals by phone at **1-800-541-4802** or email at **recall@acellapharma.com** for further information regarding this recall.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.